Novo Nordisk INC. v. Lupin LTD.

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Lupin Ltd. (India)
  • Plaintiff's Counsel: Fenwick & West LLP
• Case Identification: 1:23-cv-04027, D.N.J., 07/27/2023
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant conducts business in the state, has a presence there, and has previously litigated and filed counterclaims in the district, thereby availing itself of the jurisdiction. As a foreign corporation, venue is alleged to be proper in any district where personal jurisdiction exists.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Victoza® (liraglutide) product constitutes an act of infringement of two U.S. patents covering the drug's formulation and its injection pen mechanism.
• Technical Context: The patents relate to a stable, injectable pharmaceutical formulation for a GLP-1 agonist peptide used in diabetes treatment and a low-friction push-button mechanism for a pen-style injection device.
• Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendant's submission of ANDA No. 215421. The complaint states that on June 12, 2023, Defendant sent a Notice Letter containing a Paragraph IV certification, alleging that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its generic product. Plaintiff filed this suit within the 45-day statutory window, which typically triggers an automatic 30-month stay of FDA approval for the ANDA.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and For Use in Injection Devices"

The Invention Explained

• Problem Addressed: The patent's background section states that common isotonicity agents used in peptide drug formulations, particularly mannitol, can cause significant problems during manufacturing and administration ʼ833 Patent, col. 1:29-35 Mannitol may crystallize, creating deposits on production equipment that reduce manufacturing yield and require frequent cleaning, and can also clog the fine needles of injection devices used by patients ʼ833 Patent, col. 1:35-49
• The Patented Solution: The invention replaces mannitol with propylene glycol as the isotonicity agent in a peptide formulation ʼ833 Patent, abstract This substitution is described as reducing deposits on production equipment and minimizing the clogging of injection devices, thereby making the formulation better suited for both large-scale production and patient use ʼ833 Patent, col. 1:50-54 Figure 7 of the patent visually contrasts a needle clogged with deposits from a mannitol formulation with a clean needle used with the propylene glycol formulation.
• Technical Importance: For widely used, self-administered injectable drugs, ensuring both manufacturing efficiency and reliable, safe device operation for the patient are commercially and medically critical.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-31 Compl. ¶22 Independent claim 1 is representative of the composition claims.
• The essential elements of independent claim 1 include:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist
  • a disodium phosphate dihydrate buffer
  • propylene glycol
  • propylene glycol is present in a final concentration of from about 1 mg/ml to about 100 mg/ml
  • the formulation has a pH of from about 7.0 to about 10.0

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

• Problem Addressed: In pen-style injection devices where a dose is set by rotating a dial, the user must push a button that causes a driving part to rotate back to its original position to deliver the dose ʼ893 Patent, col. 1:26-34 The patent describes that friction between the user's stationary finger on the push button and the rotating internal driving part requires the user to apply a larger force to overcome this resistance, which can be an impediment to proper use ʼ893 Patent, col. 1:45-56
• The Patented Solution: The invention discloses a "push button connection" designed to minimize this rotational friction ʼ893 Patent, abstract It achieves this by creating a "pivot bearing" between the push button and the rotating driving part, which minimizes the contact surface area and reduces the radius of the resulting friction force ʼ893 Patent, col. 1:57-62 Figure 1 of the patent illustrates the assembly, showing the pivot point (18, 22) between the button (10) and the driving part protrusion (21).
• Technical Importance: Reducing the actuation force required to deliver an injection enhances the usability and accessibility of self-injection devices, particularly for patients with arthritis or diminished hand strength.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 Compl. ¶28 Claim 1 is the sole independent claim.
• The essential elements of independent claim 1 include:
  • A push button connection for an injection device
  • comprising a push button mountable on a driving part, with the driving part being rotatable relative to the push button
  • the push button has a bore with a bottom surface that surrounds a protrusion on the driving part
  • the protrusion has a top surface
  • a pivot bearing is formed between the bore's bottom surface and the protrusion's top surface
  • when a user presses the button, force is directed to the driving part, and the driving part rotates relative to the push button

III. The Accused Instrumentality

• Product Identification: Defendant's proposed generic version of liraglutide injection solution, 18 mg/3 ml (6 mg/ml), for which it seeks FDA approval via ANDA No. 215421 Compl. ¶10 Compl. ¶17
• Functionality and Market Context: The accused product is a generic version of Plaintiff's Victoza® product Compl. ¶1 Compl. ¶17 The complaint alleges that the Defendant's ANDA relies on the Victoza® New Drug Application and contains data to demonstrate bioequivalence Compl. ¶18 This suggests the accused product contains the same active pharmaceutical ingredient (liraglutide) and is intended for the same therapeutic use, namely the treatment of type 2 diabetes. The infringement allegations against the '893 patent suggest the product will be delivered via a pen-style injection device.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed infringement theory or claim chart for either patent-in-suit. The infringement allegations are based on the statutory act of infringement under 35 U.S.C. § 271(e)(2)(A), which arises from the submission of an ANDA seeking to market a generic drug prior to the expiration of patents listed in the FDA's Orange Book Compl. ¶1 Compl. ¶16 The implicit theory of infringement is that because the Defendant's product is a generic copy intended to be bioequivalent to Victoza®, its formulation and the device used to deliver it will necessarily practice the inventions claimed in the patents-in-suit Compl. ¶15 Compl. ¶18

• '833 Patent Infringement Allegations:

  • Identified Points of Contention: The central dispute will likely concern whether the formulation described in the Defendant's ANDA meets every limitation of the asserted claims. A key question for the court may be one of compositional identity: Does the accused formulation contain propylene glycol as an isotonicity agent within the claimed concentration range (e.g., "about 1 mg/ml to about 100 mg/ml"), use a "disodium phosphate dihydrate buffer," and have a pH within the claimed range, or did the Defendant formulate a bioequivalent product that "designs around" one of these elements? The Defendant's Paragraph IV certification also raises the question of validity, which could focus on whether the substitution of propylene glycol for mannitol was obvious to a person of ordinary skill in the art Compl. ¶19

• '893 Patent Infringement Allegations:

  • Identified Points of Contention: The analysis will focus on the mechanical structure of the injection device intended for use with the Defendant's generic drug. A primary question for the court may be one of structural scope: Does the connection between the push button and the driving part in the Defendant's device constitute a "pivot bearing" as that term is defined by the patent, or does it employ a different, non-infringing mechanism to achieve low-friction actuation? The Defendant's non-infringement position, as stated in its Paragraph IV certification, suggests it may argue for a narrow construction of the claim terms to exclude its specific device design Compl. ¶19

V. Key Claim Terms for Construction

• For the '833 Patent:

  • The Term: "about"
  • Context and Importance: This term modifies the numerical ranges for both the propylene glycol concentration and the pH in independent claim 1. The breadth of this term is critical, as it determines the boundaries of the claimed ranges. Practitioners may focus on this term because a narrow interpretation could allow the Defendant to argue non-infringement if its product's parameters are close to, but not exactly within, the specified numerical limits.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification discloses several exemplary formulations with varying concentrations, such as "14.0 or 14.3 mg.ml" for propylene glycol, suggesting that the inventors contemplated some degree of variation around specific values ʼ833 Patent, col. 20:16
    • Evidence for a Narrower Interpretation: A party could argue that in the context of pharmaceutical chemistry, where precision is important for stability and safety, the term "about" should be construed narrowly to encompass only minor variations that do not materially affect the formulation's properties as described in the patent.

• For the '893 Patent:

  • The Term: "pivot bearing"
  • Context and Importance: This term is the central structural element of independent claim 1 and defines the core of the purported inventive concept for reducing friction. The entire infringement analysis for this patent will likely depend on the construction of this term.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification describes the functional goal of the invention as minimizing friction by reducing the surface area of interaction between the push button and the driving part ʼ893 Patent, col. 1:57-62 This could support a broader, more functional definition that covers any structure creating a point-like contact to allow for low-friction relative rotation.
    • Evidence for a Narrower Interpretation: The patent's preferred embodiment describes a specific structure: a "raised pointer forming a pivot" on the button that contacts the top surface of a protrusion on the driving part ʼ893 Patent, col. 3:63-65 ʼ893 Patent, Fig. 1 This could support a narrower construction limited to the specific point-on-plane structural arrangement shown in the figures, or one very similar to it.

VI. Other Allegations

• Indirect Infringement: The complaint does not plead separate counts for induced or contributory infringement. The action is based on the direct, albeit artificial, act of infringement established by 35 U.S.C. § 271(e)(2)(A) for the filing of an ANDA Compl. ¶21 Compl. ¶27
• Willful Infringement: The complaint alleges that the Defendant "was aware of the '833 patent when it submitted its ANDA" and "was aware of the '893 patent when it submitted its ANDA" Compl. ¶25 Compl. ¶31 This allegation of pre-suit knowledge, evidenced by the Defendant's Paragraph IV certification letter Compl. ¶19, forms the basis for Plaintiff's request for a finding of an exceptional case and an award of attorneys' fees under 35 U.S.C. § 285 Compl., Prayer for Relief F

VII. Analyst's Conclusion: Key Questions for the Case

This litigation appears to center on the interplay between the strict requirements of generic bioequivalence and the precise scope of patent claims. The key questions for the court will likely be:

• A core issue will be one of compositional scope: Does the accused generic drug formulation, in achieving bioequivalence with Victoza®, necessarily fall within the claimed pH and concentration ranges of the '833 patent, or has the Defendant successfully "designed around" the claims by using, for example, a concentration of propylene glycol just outside the range defined by the term "about"?
• A second core issue will be one of mechanical definition: Does the push-button mechanism in the Defendant's delivery device meet the structural limitations of the '893 patent, specifically by incorporating what the court construes to be a "pivot bearing," or does it achieve a similar functional outcome through a mechanically distinct, non-infringing design?
• A foundational question, underlying the entire dispute, will be one of validity: As raised by the Defendant's Paragraph IV certification, were the inventions, particularly the substitution of propylene glycol for mannitol in the '833 patent, obvious to a person of ordinary skill in the art at the time the invention was made?